Skip to content

Jessica A. Johnson

4 papers in the library · 214 citations · publishing 2017-2023

Papers

Sort Most recent Most cited

Blurring the Lines Between “Good” and “Bad” Religion: John Modern's Neuromatic

Religious Studies Review September 1, 2023 Jessica A. Johnson

Chicago: University of Chicago Press, 2021. Pp. xv + 426. Paper $32.50. “In the MRI I experienced the invisible tendrils of discourse…a particularly powerful construction of the social. For in the MRI I became aware of my paranoia, mindful of how theories of information, feedback, and self-organization…frame the social as comprised of discrete individuals in a giant communication machine” (20)....

Efficacy of Intravenous Ketamine in Adolescent Treatment-Resistant Depression: A Randomized Midazolam-Controlled Trial

FOCUS: The Journal of Lifelong Learning in Psychiatry April 1, 2022 Jennifer B. Dwyer, Angeli Landeros‐Weisenberger, Jessica A. Johnson et al. 51 citations

Objective: Adolescent depression is prevalent and is associated with significant morbidity and mortality. Although intravenous ketamine has shown efficacy in adult treatment-resistant depression, its efficacy in pediatric populations is unknown. The authors conducted an active-placebo-controlled study of ketamine's safety and efficacy in adolescents. Methods: In this proof-of-concept...

Efficacy of Intravenous Ketamine in Adolescent Treatment-Resistant Depression: A Randomized Midazolam-Controlled Trial.

American Journal of Psychiatry March 3, 2021 J. Dwyer, Angeli Landeros‐Weisenberger, Jessica A. Johnson et al. 163 citations

OBJECTIVE Adolescent depression is prevalent and is associated with significant morbidity and mortality. Although intravenous ketamine has shown efficacy in adult treatment-resistant depression, its efficacy in pediatric populations is unknown. The authors conducted an active-placebo-controlled study of ketamine's safety and efficacy in adolescents. METHODS In this proof-of-concept randomized,...

Ketamine for Social Anxiety Disorder: A Randomized, Placebo-Controlled Crossover Trial.

Neuropsychopharmacology August 29, 2017 Jerome H Taylor, Angeli Landeros‐Weisenberger, Catherine Coughlin et al.

Many patients with social anxiety disorder (SAD) experience inadequate symptom relief from available treatments. Ketamine is a potent N-methyl-D-aspartate receptor antagonist with a potentially novel mechanism of action for the treatment of anxiety disorders. Therefore, we conducted a double-blind, randomized, placebo-controlled crossover trial in 18 adults with DSM-5 SAD and compared the...

DOI: 10.1038/npp.2017.194 (opens in new tab) Full text (opens in new tab) Ketamine Humans Receptors, n-methyl-d-aspartate Anti-anxiety agents +5